Figure 6.

Comparative analysis of the properties of proof-of-concept and optimized bispecific antibodies. (A and B) Micro-scale triage composed of differential scanning fluorescence profiling and thermal inactivation assays allow the selection of bispecific with improved serum and aggregation stabilities. The proof-of-concept bispecific molecule is inferior to a stabilized one in both microscopic (measured by differential scanning fluorimetry (A)) and macroscopic properties [measured by percent of binding activity remaining after 3 day incubation in mouse serum at 37°C (B)]; (C) Optimized bispecific antibody display stronger cellular binding compared to proof-of-concept one. The binding to cancer cell line expressing both GFR1 and GFR2 was measured by fluorescence-activated cell sorting.